Taiho Ventures

Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators

Retrieved on: 
Thursday, April 22, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Allosteric regulation, Proteins, Phosphatase, Anavo Therapeutics, M Ventures, INKEF Capital, Taiho Ventures, Bioqube Ventures, ANAVO THERAPEUTICS, M VENTURES, INKEF CAPITAL, TAIHO VENTURES, BIOQUBE VENTURES

b'Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, debuted today with a EUR 20 million (approx.

Key Points: 
  • b'Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, debuted today with a EUR 20 million (approx.
  • Anavo\xe2\x80\x99s mission is to pioneer systematic drug discovery and development approaches aimed at phosphatases, a rich and largely untapped therapeutic target class.
  • We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators.
  • In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.

Dren Bio announces a $60M Series A financing

Retrieved on: 
Friday, October 16, 2020
Oncology, Professional services, Health, Genetics, Venture capital, Pharmaceutical, Biotechnology, Dren, Articles, High Performance Computing Modernization Program, Protein aggregation, Biotechnology, Protein, Branches of biology, Health, Dren Bio, SR One, Taiho Ventures, 8VC, BVF Partners L.P., HBM Healthcare Investments, Mission BioCapital, Alexandria Venture Investments

Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round.

Key Points: 
  • Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round.
  • Dren previously closed a $6 million Seed Financing in 2019 led by 8VC with participation by Mission BioCapital and prominent industry veterans.
  • The goal of our Series A financing is to bring two drug candidates to the clinic.
  • Dren Bio is a San Carlos, CA based biotechnology company developing powerful protein engineering technologies to deplete cells, protein aggregates and other disease-causing agents.